Investseekers points to Fierce Pharma's refreshed chart showing how Novo's oral Wegovy and Lilly's Foundayo launches are tracking over time.
Recap by typeshit. Post by Investseekers on X.
8:09
Regan Archibald gives his take on the timeline for retatrutide reaching patients. Tap through for his view on where the drug stands.
Morse says bar and restaurant workers have seen younger adults drink less, framing it as a broad change in the alcohol industry.
Bazaar India's new issue looks at collagen loss and skin laxity concerns tied to fast GLP-1 weight loss, and how beauty brands are responding.
Novo also reported 25% average weight loss in women on CagriSema in a post-hoc trial analysis, while BMO flagged Ozempic losing US share.
Yale Medicine says 5% to 10% of people on GLP-1 weight loss drugs see little result, and points to diet as one factor that can blunt the effect.
Hevia Cosmetic Dermatology posts a short clip of Dr. Oscar Hevia giving his take on the experimental GLP-1 drug retatrutide.
Loading…